Lipotec targets skin inflammation with new peptides
According to the company, Telangyn, a tetrapeptide protects the skin against exogenous factors causing redness by reducing the levels of interleukins (IL-6 and IL-8) involved in the inflammatory process.
From in vivo tests of two daily applications of a cream containing 2 per cent Telangyn, Lipotec reports a decrease of 7.5 per cent of the intensity of redness.
Delisens, a hexapeptide is also designed for sensitive and allergic skins but with no visible external signs. Lipotec says it decreases the activity of PAR-2, the proteases receptor involved in the process of neurogenic inflammation (substance P and CGRP) and in the production of Interleukins IL-6 and IL-8 as well as in the weakening of the skin’s barrier function.